^
    Back
    Association details:
    Biomarker:MYC expression + BCL2 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Yinuokai (orelabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

    Published date:
    11/02/2023
    Excerpt:
    Double-expression lymphoma (DEL), a type of diffuse large B cell lymphoma (DLBCL) with co-expression of MYC and BCL2 proteins without gene rearrangements...The combination of orelabrutinib and RCHOP showed encouraging efficacy and a tolerable safety profile in DEL DLBCL in this preliminary analysis.
    Secondary therapy:
    R-CHOP
    DOI:
    https://doi.org/10.1182/blood-2023-187906